RELATIONSHIP BETWEEN DEVELOPMENT OF DIARRHEA AND THE CONCENTRATION OF SN-38, AN ACTIVE METABOLITE OF CPT-11, IN THE INTESTINE AND THE BLOOD-PLASMA OF ATHYMIC MICE FOLLOWING INTRAPERITONEAL ADMINISTRATION OF CPT-11

被引:152
作者
ARAKI, E
ISHIKAWA, M
IIGO, M
KOIDE, T
ITABASHI, M
HOSHI, A
机构
[1] NATL CANC CTR,DIV CHEMOTHERAPY,CHUO KU,TOKYO 104,JAPAN
[2] NATL CANC CTR,DIV EXPTL ANIM,CHUO KU,TOKYO 104,JAPAN
[3] NATL CANC CTR,DIV PATHOL,CHUO KU,TOKYO 104,JAPAN
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 1993年 / 84卷 / 06期
关键词
SN-38; ATHYMIC MOUSE; DIARRHEA; HEMORRHAGIC COLITIS;
D O I
10.1111/j.1349-7006.1993.tb02031.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Severe diarrhea occurred during daily intraperitoneal administration of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) at a dose of 50 mg/kg in athymic mouse. Serial determination of CPT-11 and 7-ethyl-10-hydroxycamptothecin (SN-38), with the use of an on-line solid extraction HPLC system, demonstrated that much higher levels of the compounds are retained in the intestine and the blood plasma after five consecutive daily injections than after a single injection. Histologic examination of the gastrointestinal tract showed hemorrhagic colitis on day 7 and later after five consecutive daily injections of CPT-11. The direct cause of diarrhea associated with CPT-11 administration is considered to be enterocolitis caused by high levels of SN-38 and/or CPT-11 retained for a long period in the intestine.
引用
收藏
页码:697 / 702
页数:6
相关论文
共 11 条
  • [1] CHARACTERIZATION OF A MAMMALIAN MUTANT WITH A CAMPTOTHECIN-RESISTANT DNA TOPOISOMERASE-I
    ANDOH, T
    ISHII, K
    SUZUKI, Y
    IKEGAMI, Y
    KUSUNOKI, Y
    TAKEMOTO, Y
    OKADA, K
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) : 5565 - 5569
  • [2] FURUTA T, 1988, JPN J CANC CHEMOTHER, V15, P2757
  • [3] KANEDA N, 1990, CANCER RES, V50, P1715
  • [4] KAWATO Y, 1991, CANCER RES, V51, P4187
  • [5] KAWATO Y, 1987, 46TH P JPN CANC ASS, P408
  • [6] KUNIMOTO T, 1987, CANCER RES, V47, P5944
  • [7] NEGORO S, 1991, JPN J CANC CHEMOTHER, V18, P1013
  • [8] PHASE-I STUDY AND PHARMACOKINETICS OF CPT-11 WITH 5-DAY CONTINUOUS INFUSION
    OHE, Y
    SASAKI, Y
    SHINKAI, T
    EGUCHI, K
    TAMURA, T
    KOJIMA, A
    KUNIKANE, H
    OKAMOTO, H
    KARATO, A
    OHMATSU, H
    KANZAWA, F
    SAIJO, N
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (12) : 972 - 974
  • [9] AN EARLY PHASE-II STUDY OF CPT-11 - A NEW DERIVATIVE OF CAMPTOTHECIN, FOR THE TREATMENT OF LEUKEMIA AND LYMPHOMA
    OHNO, R
    OKADA, K
    MASAOKA, T
    KURAMOTO, A
    ARIMA, T
    YOSHIDA, Y
    ARIYOSHI, H
    ICHIMARU, M
    SAKAI, Y
    OGURO, M
    ITO, Y
    MORISHIMA, Y
    YOKOMAKU, S
    OTA, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (11) : 1907 - 1912
  • [10] Takeuchi S, 1991, JPN J CANC CHEMOTHER, V18, P1681